A Rare Presentation of Prostatic Adenocarcinoma Metastasized to the Occipito-Parietal Bones

Özett

Anahtar Kelimeler
Prostat Adenokarsinom; Oksipito-Parietal Kemik; Kafatası Metastazı

Abstract
Prostate adenocarcinoma has a strong tendency to metastasize to bone, particularly axial skeleton occurs at high frequency in patients with that causing significant morbidity and mortality especially. We present a rare case of prostatic adenocarcinoma having metastatic occipito-parietal bone involvement. Apart from bone, brain is also a common site of metastasis but the involvement of the occipito-parietal bone is extremely unusual. Occipito-parietal bone metastasis from prostatic adenocarcinoma was the initial presentation which was observed in our patient. This is the first case of its kind in the literature where the prostatic carcinoma had metastasized to the occipito-parietal bone of the skull without any symptomatology of prostatic adenocancer involvement.

Keywords
Prostate Adenocancer; Occipito-Parietal Bone; Skull Metastasis

DOI: 10.4328/JCAM.1136
Received: 06.06.2012 Accepted: 25.06.2012 Printed: 01.07.2015
Introduction
Prostatic adenocarcinoma has a strong tendency to metastasize to bone particularly axial skeletal bone and less commonly to the cranium. However, occipito-parietal bone involvement is rare. Skull metastasis must be kept in mind when considering the differential diagnosis of a skull tumor [1]. Most metastatic skull lesions are asymptomatic, but they can cause severe disability due to compression of dural sinuses and cranial nerves [2]. Skull metastases are rarely diagnosed clinically, but are frequently found in autopsies [2]. Despite the fact that hematogenous skull metastases can derive from nearly all types of tumors, breast cancer is associated with the highest rate of metastatic skull lesions. This is the first case of its kind in the literature where the prostatic carcinoma had metastasized to the occipito-parietal bone of the skull without any symptomatology of prostatic adenocarcinoma involvement. We present a rare case of prostatic adenocarcinoma presenting with metastatic occipito-parietal bone involvement.

Case Report
A 75-year-old man presented with only isolated serum prostate-specific antigen (PSA) elevation to our clinic. There was a history of hyperlipidemia, diabetes mellitus and cholecystectomy operation. Physical examination was unremarkable. The patient denied any urinary symptoms. Serum total PSA measured before digital rectal examination (DRE) was 23.13 ng/ml. Basic laboratory examinations of complete blood count, serum biochemistry, and urine analysis were normal except cholesterol and glucose levels. DRE revealed an enlarged, firm prostate gland. Transrectal ultrasound guided prostate needle biopsy was performed in this patient. The pathological examination revealed adenocarcinoma of the prostate (Gleason 4+4). Abdominal computed tomography (CT) scan and whole-body bone scintigraphy were performed in this patient. Abdominal CT scan revealed heterogeneous parenchymal density of the prostate and the other structures were normal. Bone scintigraphy revealed occipito-parietal bone metastases (Figure 1). There was no history of trauma in our patient. After bone scintigraphy, magnetic resonance imaging (MRI) was performed and revealed 17 mm osteolytic metastatic mass in occipito-parietal bone (Figure 2). LHRH agonist and bicalutamide treatment was started for this patient. Serum PSA decreased below 1.09 ng/ml with in 3 months. The patient had no evidence of PSA biochemical failure have not reappeared for 6 months. His serum PSA measured was 0.069 ng/ml at 6 months follow-up and occipito-parietal bone metastatic lesion was an improvement in MRI at 6 months follow-up.

Discussion
Patients with skull metastases were characterized by higher age, shorter duration of symptoms, and less frequently presented with neurological deficit, when compared to primary skull tumors and benign tumor-like lesions [3]. Despite the fact that breast cancer is associated with the highest rate of metastatic skull lesions, nearly all types of tumors (lung, prostate, thyroid carcinoma, malignant melanoma) can cause hematogenous skull metastases [3]. Skull metastases cause local swelling that is usually painless, and rarely they lead to neurological dysfunction. The differential diagnosis of metastasis should always be considered when a lytic skull lesion is identified. Multiplicity, irregular edges, and absence of peripheral sclerosis should arouse suspicion of malignancy [8]. Surgical excision cannot influence the underlying disease but can be achieved with low morbidity, and the mean survival time after the development of a skull metastasis is approximately 20 months [3]. Paget disease and multiple myeloma were excluded, because the patient with primary diagnosis of prostate adenocarcinoma has only one skull lesion which shows osteoblastic activity. In addition, there is no history of trauma in a patient.

Prostatic adenocarcinoma tends to spread to the axial bony skeleton and rarely to the cranium. The most common sites are the spine, sacrum and pelvis. Occipito-parietal metastases caused by prostate cancer are rare. It is not unusual in these sites for the bone metastases to become symptomatic before there is any recognition of the primary lesion [4]. There are a few reported skull metastatic cases. The other study reported a case of metastatic prostatic adenocarcinoma presenting with parietal bone involvement [5] and other study reported two cases with temporal bone involvement [6]. Occipito-parietal bone metastases of prostate adenocarcinoma have not been reported in the literature before. In our patient is the first case of its kind in the literature where the prostatic carcinoma had metastasized to the occipito-parietal bone of the skull without any symptomatology of prostatic adenocarcinoma involvement. The prognosis of these patients seems to depend on the effectiveness of hormonal treatment [3]. Most cases of metastatic prostatic adenocarcinoma can be controlled with hormone therapy, either by the means of surgical castration or medically with the use of LHRH analogues. Response rates are around 85%.
with a median time to progression of 18–24 months before becoming hormone-refractory [7].

In conclusion, awareness that metastatic prostatic adenocarcinoma may present with occipito-parietal bones involvement and without any symptomatology should lead the clinician to review the radiological appearance. Our case is intended to alert the reader of this rare site of metastasis from the prostate.

Acknowledgement

“This manuscript has been revised for language mistakes by a native speaker and professional medical editor of English (Safak Ugur, PhD English and American Literature- Writing Academic English-Middle East Technical University-Modern Languages dept.) for 17 years’

Competing interests

The authors declare that they have no competing interests.

References


How to cite this article: